STOCK TITAN
  1. Home
  2. News
  3. DCTH

Delcath Systems Inc - DCTH STOCK NEWS

Welcome to our dedicated news page for Delcath Systems (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Systems.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Delcath Systems's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Delcath Systems's position in the market.

News
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Delcath Systems, Inc. announces the granting of an equity award to an individual as an inducement for employment, totaling 30,000 shares of common stock with an exercise price of $4.77. The options vest over a two-year period and are subject to the employee's continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
none
-
News
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Rhea-AI Summary
Delcath Systems, Inc. increases its 2024 Treatment Site Activation Guidance to 20 sites and reports business highlights and financial results for Q4 and FY 2023. The company achieved significant milestones, including the first commercial use of HEPZATO KIT™, site activations, updated guidance, CMS approval, patient access program launch, private placement financing, and new COO appointment. Financially, Delcath had cash equivalents of $32.5 million as of December 31, 2023, with total revenue of $0.5 million for Q4 and $2.1 million for FY 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
earnings
-
News
Delcath Systems Closes $7 Million Private Placement
Rhea-AI Summary
Delcath Systems, Inc. closes a private placement, selling 876,627 shares of common stock and 1,008,102 pre-funded warrants, raising approximately $7 million. The company plans to use the proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
News
Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call
Rhea-AI Summary
Delcath Systems, Inc. (DCTH) to host conference call to discuss Q4 and year-end results for 2023 and provide business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
conferences earnings
-
News
Delcath Systems Appoints Martha S. Rook as Chief Operating Officer
Rhea-AI Summary
Delcath Systems, Inc. (DCTH) appoints Martha S. Rook as Chief Operating Officer, bringing over 25 years of industry experience in molecular biology and biologics development. Ms. Rook's background includes leadership roles at insitro and Sigilon Therapeutics, with a focus on complex combination products. She also spent 13 years at MilliporeSigma. The Company granted Ms. Rook an equity award of 125,000 shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
management
-
News
Delcath Systems Announces $7 Million Private Placement
Rhea-AI Summary
Delcath Systems, Inc. (DCTH) announces a private placement transaction with accredited investors, issuing common stock and pre-funded warrants, expecting gross proceeds of $7 million. The company plans to utilize the funds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
none
News
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Delcath Systems, Inc. (DCTH) granted equity awards to three new employees totaling 46,000 shares at an exercise price of $4.17 per share. The options vest over 3 years and were granted under the 2023 Inducement Plan, in accordance with NASDAQ rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
none
-
News
Delcath Systems to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Delcath Systems, Inc. (DCTH) will attend investor conferences to discuss its focus on treating liver cancers. Management will be at Leerink Partners Global Biopharma Conference on March 13, 2024, in Miami Beach, FL, and the 36th Annual ROTH Conference on March 18 - 19, 2024, in Dana Point, CA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
conferences
-
News
Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)
Rhea-AI Summary
Delcath Systems, Inc. (DCTH) launches Healthcare Setting Locator for HEPZATO KIT, a liver-directed treatment for metastatic uveal melanoma patients. The Locator aims to assist patients, caregivers, and healthcare providers in finding treatment sites and accessing necessary information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
News
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Delcath Systems, Inc. announces the granting of equity awards to three new employees as a material inducement to their employment. The grant includes the right to purchase 50,000 shares of the company's common stock at an exercise price of $4.79, with vesting over a period of three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock DCTH logo
Delcath Systems Inc

Nasdaq:DCTH

DCTH Rankings

#4037 Ranked by Market Cap
#1117 Ranked by Stock Gains
N/A Ranked by Dividends

DCTH Stock Data

125.92M
21.10M
3.21%
27.87%
3.68%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
New York

About DCTH

delcath systems, inc. (nasdaq- dcth) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. our proprietary product---melphalan hydrochloride for injection for use with the delcath hepatic delivery system (melphalan/hds)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. delcath is in late-stage clinical development in the united states with initial commercial activities in europe, where the melphalan/hds is marketed as a ce marked device under the trade name delcath hepatic chemosat® delivery system for melphalan (chemosat). our commercial strategy for chemosat is to steadily grow clinical adoption in major european markets and utilize physician experience to support appeals for reimbursement. since launch over 250 chemosat treatments have been performed at over 20 leading european cancer centers. in 2016, we launched our focus pivotal study in hepatic dominant ocular